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Summary 
immunoglobulin (ig) heavy/light chain (hlc) is a novel antibody based 
assay that separately measures in pairs the light chain types of each 
ig class generating ratios of monoclonal ig/background polyclonal ig 
concentrations. Free light chain (Flc) assay measures unbound κ and λ 
chains. the aim of the present study was to assess the prognostic impact 
of hlc and Flc assays in multiple myeloma (MM) and igM malignant 
lymphoma (Ml) patients with real long term survival. Measurements 
of serum hlc and Flc concentrations were performed in 23 MM and 
12 ML patients with survival exceeding 10 years and 43 (19 MM, 24 ML) 
patients with survival not exceeding 5 years. HLC and FLC ratios at dia-
gnosis were less abnormal in patients with survival exceeding 10 years 
than in patients with survival up to 5 years (p=0.03). The differences in 
median values were manifold. However, in patients with survival over 10 
years highly abnormal HLC ratio (<0.022 or >45) was found in 3 MM 
patients and 7 ML patients and highly abnormal FLC ratio (<0.1 or >30) 
was found in 5 MM patients and in 1 ML patient. In conclusion, serum 
hlc and Flc measurements at MM diagnosis provide prognostic in-
formation, despite that even in MM patients with survival exceeding 
10 years in 15% of them at diagnosis serum HLC and FLC ratios may be 
highly abnormal.
Key words: heavy/light chain assay, Free light chains, Multiple myeloma, 
Waldenström macroglobulinemia, survival
StreSzczenie 
opracowany ostatnio immunoglobulinowy test „hevylite” hlc (heavy/
light chain) pozwala na osobne mierzenie typów łańcuchów lekkich w pa-
rach każdej klasy immunoglobulinowej i oznaczanie stosunku stężenia 
monoklonalnej immunoglobuliny do stężenia poliklonalnej immunoglo-
buliny tej samej klasy. Test FLC (free light chain) oznacza wolne lekkie 
łańcuchy κ i λ, niezwiązane z cząsteczką immunoglobulinową. Celem ak-
tualnych badań była ocena wartości prognostycznej oznaczania w chwili 
rozpoznania choroby hlc i Flc w surowicy chorych na szpiczaka plazmo-
cytowego i chłoniaka złośliwego IgM z rzeczywiście długim czasem prze-
życia. Wykonano oznaczenia stężenia w surowicy HLC i FLC u 23 cho-
rych na szpiczaka i 12 na chłoniaka z czasem przeżycia ponad 10 lat 
oraz u 43 chorych (19 na szpiczaka, 24 na chłoniaka) z czasem przeżycia 
nieprzekraczającym 5 lat. Wartości stosunku HLC i stosunku FLC w chwili 
rozpoznania choroby były w mniejszym stopniu nieprawidłowe u chorych 
z czasem przeżycia ponad 10 lat niż u chorych z czasem przeżycia po-
niżej 5 lat (p=0,03). Różnica w wartościach średnich była wielokrotna. 
Jednakże u chorych z czasem przeżycia ponad 10 lat wysoce nieprawi-
dłowe wartości stosunku HLC (<0,022 lub >45) stwierdzono u 3 cho-
rych na szpiczaka plazmocytowego i 7 chorych na chłoniaka IgM, a wy-
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introduction
Recently, an assay for serum immunoglobulin free 
light chains (FLCs) has become available for clinical 
use [1] and is currently applied to monitor patients 
with plasma cell disorders [2–4]. The assay allows 
quantitation of kappa and lambda chains that are 
not bound to intact immunoglobulin molecules, and 
allows determination of clonality based on the kappa 
to lambda ratio. An abnormal FLC ratio indicating 
presence of monoclonal free light chains has been 
recently shown to be an independent risk factor for 
progression in monoclonal gammopathy of undeter-
mined significance (MGUS) and for progression of 
smoldering (asymptomatic) multiple myeloma (MM) 
[5, 6] and solitary plasmacytoma of bone [7]. Snozek 
et al. [8] and Kyrtsonis et al. [9, 10] suggest that the 
serum FLC ratio at initial diagnosis is an important 
predictor of prognosis in myeloma and can be incor-
porated into the International Staging System [11] for 
improved risk stratification. 
In 2009 Bradwell et al. [12] developed immunoglob-
ulin heavy/light chain immunoassays – “Hevylite” 
(HLC). Availability of antibodies which bind to con-
formational epitopes spanning the junctional regions 
between bound κ or λ light chains and their respec-
tive heavy chain partners has allowed the specific 
measurement of serum IgGκ, IgGλ, IgAκ, IgAλ, IgMκ 
and IgMλ concentrations. In turn, this has enabled 
the calculation of IgGκ/IgGλ, IgAκ/IgAλ and IgMκ/
IgMλ ratios (heavy/light chain or HLC ratios) for indi-
vidual patients. Separate measurements of the κ and 
λ light chain types of IgG, IgA and IgM allow evalua-
tion of individual tumor clones and give quantitative 
information about the immunosuppression of each 
non-tumor immunoglobulin. Measurement of mol-
ecule pairs, such as IgGκ/IgGλ, IgAκ/IgAλ, IgMκ/
IgMλ, would indicate clonality in the same manner as 
serum free light chain (FLC) κ/λ ratios [1].
Until now, apart from a key Bradwell’s et al. [12] 
and our [13] publications, and case report [14], there 
appeared congress reports on the results of the use 
of nephelometric measurement of individual immu-
noglobulin κ/λ ratios in assessment of monoclonal 
gammopathies including evaluation of prognostic 
value of Hevylite assays in these diseases [15–21]. The 
aim of the present study was to assess the prognostic 
impact of FLC and HLC assays in MM and IgM malig-
nant lymphoma (ML) patients with real long term – 10 
years or more – survival.
material and methods
The study included 23 MM and 12 ML patients with 
survival exceeding 10 years and 43 (19 MM, 24 ML) 
patients with survival not exceeding 5 years. All pa-
tients were diagnosed [22] and follow-up for many 
years at the Institute of Hematology and Transfusion 
Medicine in Warsaw.
Serum protein electrophoresis and immunofixa-
tion were performed on agarose media with densi-
tometric scanning using HydrasysTM 2 apparatus 
(Sebia, France) and antisera from the same company 
and also using Beckman Paragon Immunofixation 
Electrophoresis Kit.
Nephelometric immunoglobulin assays, performed 
using a Siemens BNTM II nephelometer, were used to 
measure IgGκ/IgGλ, IgAκ/IgAλ, IgMκ/IgMλ (HLC) and 
also to quantify FLC in the archived frozen and fresh 
sera of assessed patients. In this method there were 
applied antibodies (HevyliteTM Human IgG Kappa Kit; 
IgG lambda Kit, HevyliteTM Human IgA Kappa Kit; IgA 
Lambda Kit, HevyliteTM Human IgM Kappa Kit; IgM 
Lambda Kit; The Binding Site, Ltd, Birmingham, UK) 
specific for IgGκ, IgGλ, IgAκ, IgAλ, IgMκ, IgMλ and 
antibodies (Freelite®; The Binding Site, Ltd, Birming-
ham, UK) specific for κ and λ light chains in free form, 
not bound to the heavy chain. 
Statistical analysis was performed using Fisher 
exact test.
results 
Clinical and immunoglobulin study at diagnosis in 
individual MM and ML patients with survival exce-
eding 10 years are presented in tables I–III. Table IV 
presents serum FLC and HLC IgG concentrations in 
a patient with POEMS syndrome and survival exce-
eding 9 years.
Table V summarizes results of tumor and non-tu-
mor HLC immunoglobulins concentrations and HLC 
soce nieprawidłowe wartości stosunku FLC (<0,1 lub >30) stwierdzono 
u 5 chorych na szpiczaka i 1 chorego na chłoniaka. Z badań wynika, że 
oznaczanie hlc i Flc w czasie rozpoznania szpiczaka dostarcza informa-
cji prognostycznych, mimo że nawet u 15% chorych z czasem przeżycia 
ponad 10 lat w chwili rozpoznania wartości stosunku HLC i stosunku FLC 
w surowicy mogą być wysoce nieprawidłowe.
Słowa kluczowe: Hevylite, wolne łańcuchy lekkie, szpiczak plazmocytowy, 
makroglobulinemia Waldenströma, przeżycia
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Fig. 1. enormously high values of serum FLc ratios in a patient with igaκ multiple myeloma and renal failure, at diagnosis 
(a) and 17 years later at relapse (G) 
ryc. 1. Niezwykle wysokie wartości stosunku wolnych łańcuchów lekkich w surowicy chorego na szpiczaka plazmocytowego IgAκ 
i z niewydolnością nerek, w chwili rozpoznania choroby (A) i 17 lat później w czasie progresji choroby (G)
IgGκ/IgGλ, IgAκ/IgAλ, IgMκ/IgMλ ratios at diagnosis 
in sera of patients with IgG and IgA MM and IgM ML 
with survival exceeding 10 years and table VI sum-
marizes results of that study in patients with sur-
vival not exceeding 5 years. Table VII presents serum 
FLC concentrations at diagnosis in patients with MM 
and ML with survival exceeding 10 years and table 
VIII presents results of that study in patients with 
survival not exceeding 5 years. Fig. 1 illustrates 
serum and urine protein study results in a still living 
patient with MM and acute renal failure at diagnosis 
and during 17 years period of observation.
Discussion
In our previous study out of 600 assessed patients 
with MM 45 (7.5%) survived over 10 years from the 
disease diagnosis and beginning of antitumor treat-
ment. Patients with long survival were younger (me-
dian, age 55 years) at the time of diagnosis than the 
whole studied group and had normal serum creati-
nine, calcium and β2M levels. Sixty eight percent of 
these patients had stage I or II clinical progression 
[23]. Also in present study MM patients with survival 
exceeding 10 years had following characteristics at 
diagnosis: median age 52 years (range 31–78), median 
serum β2M concentration 2.46 mg/l (range 1.24–4.78), 
median serum monoclonal component concentration 
3.1 g/dl (range 1.24–4.78); 70% of these patients had 
stage I disease according to International Staging 
System criteria [11] (Tab. I–III). Present study add to 
these characteristics only slightly to moderately, in 
comparison to the general MM population, abnormal 
HLC and FLC ratios (Tab. VII–IX).
When patients were stratified according to their 
survival time over 10 years or not exceeding 5 
years serum HLC and FLC ratios at diagnosis were 
less abnormal in patients with survival exceed-
ing 10 years (p=0.03). The differences in median 
values were manifold (Tab. VII–IX). However, in 
patients with survival exceeding 10 years highly 
abnormal HLC ratio (<0.022 or >45) was found in 3 
MM patients (13.6%) and 7 ML patients (58%) and 
highly abnormal FLC ratio (<0.1 or >30) was found 
in 5 MM patients (23.8%) and in 1 ML patient (8%). 
Manier et al. [21] conducted the study in a series 
of 71 Waldenström Macroglobulinemia patients at 
diagnosis. The median serum IgM HLC ratio was 
100 (2.59–2850) and the median IgM involved HLC 
level was 21.9 (1.94–126) g/l. It is worthy to notice 
that our still living patient with MM and renal fail-
ure had at diagnosis and have also presently, 17 
years later, enormously increased serum FLC ratio 
(Fig. 1).
Previously we reported [25] the case of a male 
patient presenting with polyneuropathy, IgGλ mono-
clonal gammopathy, splenomegaly, inconsiderable 
lymphadenopathy, disseminated sclerotic and single 
lytic bone lesions, papilledema, leg edemas, discrete 
hypothyroidism and thrombocytosis. The POEMS 
syndrome was diagnosed and the patient was ini-
tially treated with the VAD regimen. No improvement 
of neuropathy was observed, but the other disease 
symptoms did not progress. One year after diagno-
sis the patient underwent myeloablative treatment, 
followed by autologous peripheral blood stem cell 
transplantation. Subjective neurological ameliora-
tion, normalization of the platelet count and stabi-
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Table I. Serum free light chain (FLc) and heavy /light chain (HLc) igG concentrations at diagnosis in individual igG multiple myeloma patients and survival 
exceeding 10 years. 
tabela i. Stężenia wolnych łańcuchów lekkich (FLC) i związanych z łańcuchem ciężkim (HLC) IgG w chwili rozpoznania choroby u chorych na szpiczaka plazmocytowego IgG 

































1. 52 IV 1987 1.27 i iggλ 3.2 9.83 27.80 0.35 6.31 95.60 0.07 120 died
2. 78 X 1991 2.65 i iggλ 3.1 <1.69 25.60 < 0.06 13.40 421.00 0.03 114 died
3. 52 XI 1987 1.36 i iggκ 3.1 37.50 1.61 23.40 99.70 11.60 8.56 197 died
4. 47 VII 1999
VIII 2008
XI 2011



















5. 52 V 1981 2.88 i iggκ 9.7 63.70 10.20 6.25 59.00 25.20 2.35 264 died
6. 60 VIII 2000 2.24 i iggκ 3.5 38.60 0.66 58.50 55.30 6.27 8.81 128 died
7. 53 I 1985
III 2011






60.10 21.50 2.80 > 312 sD
8. 50 XII 1991 4.78 ii iggλ 8.7 6.80 108.00 0.06 6.75 56.90 0.12 145 died
9. 44 I 1997
IV 2010
V 2011









14.40 116.00 0.12 >180 sD
10. 64 VII 1993 3.47 ii iggκ 3.3 11.60 1.46 7.94 46.00 5.63 8.18 123 died
11. 41 I 1995
II 2005
VI 2005
















12. 60 VIII 2003 5.11 ii iggλ 6.0 3.62 52.20 0.07 1.56 2240 0.00… > 108 pr
abbreviations: cr – complete response, Pr – partial response, SD – stabilisation of disease
Table II. Serum free light chain (FLc) and heavy /light chain (HLc) iga concentrations at diagnosis in individual iga multiple myeloma patients with survi-
val exceeding 10 years 
tabela ii. Stężenia wolnych łańcuchów lekkich (FLC) i związanych z łańcuchem ciężkim (HLC ) IgA w  chwili rozpoznania choroby u chorych na szpiczaka plazmocytowego IgA 





























1. 55 I 1986 3.89 ii igaλ 3.15 10.40 65.80 0.16 6.76 26.30 0.26 117 died
2. 69 VI 1992














4.16 > 120 sD
3. 57 III 1998 1.43 i igaκ 2.90 25.10 3.48 7.22 55.90 7.85 7.12 130 died
4. 32 III  2001VIII 2011








5. 71 III 1996 2.25 i igaκ 1.20 18.10 0.86 20.90 42.50 11.60 3.68 > 190 sD
6. 57 VI 2001I 2012








7. 41 XII 1989 1.32 i igaκ 2.38 2.42 0.47 5.13 16.50 11.40 1.45 > 168 sD
8. 31 VIII 2002II 2011








9. 43 III 1995I 2012













10. 63 I 1998 igaκ 0.26 10.30 0.17 43.00  > 156 pr
abbreviations: SD – stabilisation of disease, cr – complete  response, Pr – partial response, PD – progression of disease, mo – month
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lization of other symptoms was observed. Since that 
time for 8 years the patient was followed without 
further treatment. Stabilization of the disease was 
also reflected in stable serum immunoglobulin pic-
ture: slightly abnormal IgGκ/IgGλ HLC ratio, normal 
uninvolved IgGκ HLC concentration and normal FLC 
ratio (Tab. IV).
Some congress publications provide data on prog-
nostic value of HLC analysis in multiple myeloma and 
MGUS [16–21]. 
Avet-Loiseau et al. [16, 17] reported that heavy/
light chain specific immunoglobulin ratios at pres-
entation were prognostic for progression free sur-
vival (PFS) in the IFM 2005-01 myeloma trial. In that 
study, Kaplan Meier analysis indicated that more 
abnormal HLC ratios were associated with reduced 
PFS (> median for IgGκ and IgAκ patients, < median 
for IgGλ and IgAλ patients; p=0.007). When using 
more extreme ratios (>200 or <0.01), the significance 
level was higher increased (p=0.002). Cox regression 
analysis confirmed the association of the latter HLC 
ratios with reduced PFS (p<0.001) and indicated that 
the association was independent of and more signifi-
cant than that of β2M or albumin. The combined use 
of the extreme HLC ratios and β2M >3.5 mg/L, in a risk 
stratification model, showed significant differences in 
PFS for patients with 0, 1, or 2 adverse risk factors 
(p=0.000013). A more complex risk stratification model 
combining HLC ratios with the International Staging 
System also showed significant differences in PFS 
according to the number of risk factors (p=0.0001). The 
use of HLC ratios provides a measure of both tumor 
immunoglobulin production and immunoparesis. 
Probably, the combination of these two factors has a 
prognostic value. HLC measurements may be a useful 
addition to the current ISS assessments.
Also Ludwig et al. [19, 20] found that the ratio of 
monoclonal to polyclonal immunoglobulins assessed 
Table III. Serum free light chain (FLc) and heavy /light chain (HLc) igm concentrations at the time of diagnosis in individual patients 
with igm malignant lymphoma and survival exceeding 10 years 
tabela iii. Stężenia wolnych łańcuchów lekkich (FLC) i związanych z łańcuchem ciężkim (HLC) IgM w  chwili rozpoznania choroby u chorych z chłoniakiem 
złośliwym IgM z czasem przeżycia ponad 10 lat
case age(yr) m-protein (g/dl)










1. 37 igMκ 2.72 24.30 2.72 8.93 37.30 13.50 2.76 192
2. 62 igMκ 4.43 99.70 0.03 2680 79.50 5.35 14.90 156
3. 60 igMκ 2.20 123.00 1.91 64.20 3450 312 11.00 >168
4. 41 igMλ 1.63 1.55 29.40 0.05 24.00 39.40 0.61 >120
5. 46 igMλ 2.40 0.91 62.60 0.01 10.20 123.00 0.08 >120
6. 76 igMκ 1.10 20.20 0.19 104.00 380 13.20 28.80 >228
7. 47 igMκ 1.46 2.09 0.25 8.20 26.40 9.45 2.80 >132
8. 67 igMκ 1.88 35.20 0.06 588.0 142.00 9.08 15.70 >132
9. 60 igMλ 2.95 0.77 19.60 0.04 12.30 95.60 0.13 120
10. 44 igMκ 1.20 11.10 2.63 4.22 9.49 15.80 0.60 >120
11. 63 igMκ 2.70 18.30 0.09 192.0 22.00 11.00 2.00 >132
12. 70 igMκ 5.20 353.00 0.50 698.0 115.0 6.79 16.90 >108
Table IV. Serum free light chain (FLc) and heavy /light chain (HLc) igG concentrations at diagnosis and in the period of follow-up in 
patient with POemS syndrome and survival exceeding 9 years 
tabela iV. Stężenia wolnych łańcuchów lekkich (FLC) i związanych z łańcuchem ciężkim (HLC) IgG w chwili rozpoznania choroby  i przebiegu obserwacji w 
surowicy chorego z zespołem POEMS i czasem przeżycia ponad 9 lat







m-protein by iFe 
and SPe (g/dl)











(at diagnosis) 2.17 i
igg λ
0.80 6.60 8.20 0.80 47.10 73.30 0.64
III 2005
(after asct) 6.01 7.31 0.82
X 2011
(at follow-up) 3.82 6.85 0.56 24.10 50.60 0.47
abbreviations: aSct – autologous stem cell transplantation
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with the Hevylite test predicts prognosis, is superior 
for monitoring the course of the disease and allows 
detection of monoclonal immunoglobulin in multiple 
myeloma patients with normal or subnormal involved 
immunoglobulin isotype. In a study of 103 multiple 
myeloma patients median overall survival of the entire 
group was 37.9 months. In multivariate analysis, β2M, 
and HLC ratio were found as the only parameters cor-
relating with survival. A three tiered risk stratification 
model utilizing β2M >3.5 mg/L, and HLC > median 
value had a grater prognostic value than ISS (p=0.001 
vs p=0.09). Patients with 0 risk factors (β2M <3.5 mg/L, 
HLC ratio < median) had a 50% survival time of 118 
months, patients with 1 risk factor (either β2M >3.5 
mg/L or HLC ratio > median) had a 50% survival of 
53 months and those with both risk factors (β2M >3.5 
mg/L and HLC ratio > median) had a 50% survival 
of 29 months (p=0.001) [19]. In recent analysis when 
patients were stratified according to their presenta-
tion HLC ratios being moderately abnormal (0.022–45; 
n=51) or highly abnormal (<0.022 or >45; n=52), sur-
vival was significantly shorter in those with highly 
abnormal ratios (median 32,1 months versus median 
not reached, p=0.016). The survival rates at 5 years 
were 33.4% for the former and 58.9% for the latter 
group (p=0.01). For patients with a highly abnormal 
FLC ratio (<0.1 or >30) a statistically non-significant 
tendency for shorter survival was noted (40.8 months 
versus median not reached, p=0.08) compared to those 
with less abnormal FLC ratios (0.1–30). A risk strati-
fication prognostic model with highly abnormal HLC 
and FLC ratios as risk factors at presentation was 
developed. Overall survival was significantly different 
between patients with both, highly abnormal HLC and 
FLC ratios or only one, or none of these risk factors 
(p=0.01). The median was not reached in patients with 
0 or 1 risk factor and was 29.2 months in those with 
2 risk factors. The respective five year survival rates 
were 67.4%, 50.0% and 23.3% [20].
The serum FLC ratio at presentation has been 
shown to be an independent prognostic marker 
in multiple myeloma [8]. Also Harding et al. [15] 
reported the use of serum FLC and HLC ratios 
to predict survival in multiple myeloma patients. 
Archived presentation sera (n=186) from British 
Medical Research Council multiple myeloma tri-
als were analyzed retrospectively using sFLC and 
HLC assays. Kaplan-Meier survival curves were 
constructed to compare patients above or below the 
median value for FLC and HLC ratio and M-spike 
concentration. There was no significant difference 
in survival when analyzing intact M protein con-
centrations, serum FLC concentrations, FLC ratios 
or HLC ratios individually. Adding FLC and HLC 
ratios together there was a significantly shorter 
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the median (50% survival 949 days versus 1592 
days; p=0.02). The serum FLC ratio is likely to be 
more predictive of outcome than the concentration 
of the tumor sFLC because it includes a measure of 
immunoparesis (the denominator) as well as tumor 
production (the numerator). Use of the HLC ratio 
also incorporates a measure of immunoparesis but 
additionally, it will compensate for any reduction in 
the concentration of monoclonal immunoglobulin 
due to increased catabolism (IgG) and/or increased 
plasma volume. It is probable that the use of the 
summated sFLC and HLC ratios was more predic-
tive of outcome because there were some patients 
with very low monoclonal intact immunoglobulin 
production for whom the FLC ratio was the most 
appropriate prognostic marker and vice versa for 
patients with low FLC production [15].
A carried out in our previous study [13] evalua-
tion of actual survival time of 21 IgM gammopathy 
patients diagnosed with multiple myeloma or Wal-
denström’s macroglobulinemia and mean follow-up 
time of six years showed no statistically significant 
difference in median survival depending on the 
results of the HLC ratios tested at diagnosis amount-
ing 7 years in patients with HLC ratio values < the 
median and 5.5 years for patients with values of HLC 
ratio > the median (p=0.2738). In the present study 
highly abnormal HLC ratio (<0.022 or >45) was found 
in 7 out of 12 (58%) IgM ML patients with survival 
exceeding 10 years.
However, Koulieris et al. [26] evaluated the prog-
nostic value of IgMκ/IgMλ HLC ratios at diagnosis 
and the role of HLC ratio in disease monitoring in 
31 patients with Waldenström’s macroglobulinemia. 
Median IgM HLC ratio was significantly higher in 
patients requiring treatment at presentation than in 
those not requiring treatment. IgM HLC ratio corre-
lated with bone marrow infiltration and time to first 
treatment. A simple risk stratification model utilizing 
IgM HLC ratio > median, β2M >5 mg/L and abnormal 
LDH identified 3 prognostic groups with respect to 
survival (p<0.001) in this series with a median follow 
– up of 59 months. Authors suggest that HLC IgM and 
IgM HLC ratio seem to separate patients with a more 
aggressive disease. Leleu et al. suggest that Hevylife 
test might replace the current techinque to measure 
IgM M-spike in the years to come [28].
IgG but not IgA HLC ratios have been shown to pre-
dict malignant transformation in MGUS patients [18].
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Table VII. Serum free light chain (FLc) concentrations at diagnosis in patients with multiple myeloma (mm) and igm malignant lym-
phoma (mL) with survival exceeding 10 years 
tabela Vii. Stężenia w surowicy wolnych łańcuchów lekkich (FLC) w chwili rozpoznania choroby u chorych na szpiczaka plazmocytowego i chłoniaka 
złośliwego IgM z czasem przeżycia ponad 10 lat
n κ FLc (mg/l)
λ FLc
 (mg/l) κ/λ ratio
iggκ MM 
Median; range 7 60.1; 46–532 11.6; 5.3–25.2 8.5; 2.3–99.8
iggλ MM
Median; range 6 10.0; 6.3–14.4 105.8 ;56.9–421 0.09; 0.03–0.12
igaκ MM










Median; range 9 79.5; 9.4–3450 11; 5.3–312 11.0; 2.0–28.8
 igMλ Ml 
Median; range 3 12.3; 10.2–24.0 95.6; 39.4–123 0.13; 0.08–0.61
healthy persons
Median; range 10 13.5; 6.4–18.0 11.3; 6.6–23.3 1.0; 0.74–1.34
Table VIII. Serum free light chain (FLc) concentrations at diagnosis in patients with multiple myeloma and igm malignant lymphoma 
with survival not exceeding 5 years 
tabela Viii. Stężenia w surowicy wolnych łańcuchów lekkich (FLC) w chwili rozpoznania choroby u chorych na szpiczaka plazmocytowego i chłoniaka 
złośliwego IgM z czasem przeżycia poniżej 5 lat




Median; range 6 877; 46–11400 4.8; 1.5–9.0 189; 5–7620
iggλ MM
Median, range 4 6.0; 0.07–22.8 3.1; 51.9–760 0.01; 0.001–0.08





igMκ Ml 1 3500 6.6 531
igMλ Ml 2 2.1; 5.8 409; 103 0.01; 0.06
Table IX. comparison of serum immunoglobulin HLc ratios at diagnosis in mm patients with survival exceeding 10 years, not exce-
eding 5 years and patients enrolled to iFm 2005 trial. 
tabela iX. Porównanie wartości stosunku IgGκ/iggλ, igaκ/igaλ hlc w surowicy w chwili rozpoznania choroby u chorych na szpiczaka plazmocytowego z 





Present study iFm 2005 trial (n=339)
avet-Loiseau et al. [16, 17]
Bradwell et al. [24]
involved/un-involved HLc ratio
median, range























igaλ MM 0.09; 0.16 0.020.02–0.06
0.01
0.001–0.32
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